Background Current management of infective endocarditis include admission and treatment with parenteral antibiotics for 4 weeks - 6 weeks. Resource demands and psychological issues of present management strategy make it highly relevant to seek for alternative more lenient alternatives. Experiences with oral treatment are only sporadically described, but observational data suggest that oral treatment could be a feasible option. The investigators have in 2010 treated 12 endocarditis patients with partial oral antibiotics with a 100% success rate. Study design The POET study is a Danish multicenter, prospective, randomized, open label study. The primary aim is to show non-inferiority of partial oral treatment with antibiotics of endocarditis compared to full parenteral treatment. Stable patients (n=400) with streptococci, staphylococci or enterococci infecting the mitral valve or the aortic valve will be included. After a minimum of 10 days of parenteral treatment, patients will be randomized to oral therapy or parenteral therapy. Special recommendations for oral treatment have been developed based on expected minimal inhibitory concentrations and pharmacokinetic calculations. Patients will be followed for 6 months after completion of antibiotic therapy. The primary endpoint is a composition of all cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
400
Aalborg Sygehus
Aalborg, Denmark
Skejby Sygehus
Aarhus, Denmark
Rigshospitalet
Copenhagen, Denmark
Gentofte Hospital
Copenhagen, Denmark
Herlev Hoslpital
Copenhagen, Denmark
Hillerød Hospital
Hillerød, Denmark
Odense Sygehus
Odense, Denmark
Roskilde Sygehus
Roskilde, Denmark
The primary endpoint is a composite endpoint including all cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen
Time frame: Approximately 7 months. From randomisation until 6 months after end of study medication
Quality of life
QOL performed during the study and after completion of the study
Time frame: Approximately 7 months. From randomisation until 6 months after end of study medication
Cost of treatment
Time frame: Approximately 7 months. From randomisation until 6 months after end of study medication
Duration of antibiotic therapy
Time frame: Approximately 7 months. From randomisation until 6 months after end of study medication
Complications related to intravenous catheter
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.